California jury awards $332 million to man who blamed his cancer on use of Monsanto weedkiller
SAN DIEGO (AP) — A California jury has awarded $332 million to a man who sued chemical giant Monsanto Co. contending that his cancer was related to decades of using its Roundup weedkiller.
A San Diego Superior Court jury awarded damages Tuesday in a lawsuit filed by Mike Dennis, 57, of Carlsbad. He was diagnosed in 2020 with a rare form of non-Hodgkin’s lymphoma.
His lawsuit contended that his illness was related to Roundup’s active ingredient, glyphosate.
Dennis had treatment and has been in remission for nearly three years but there is no cure, Adam Peavy, one of his attorneys, told KNSD-TV.
Bob Melvin is coming home to San Francisco as Giants manager after an uneasy time in San Diego
Bob Melvin is leaving the San Diego Padres to manage the San Francisco Giants, AP sources say
Zoos and botanical gardens find Halloween programs are a hit, and an opportunity
“His doctors have told him it’s going to come back and we’re just waiting to see if that happens,” Peavy said.
The jury found that Monsanto, which is now a division of pharmaceutical and biotechnology giant Bayer, failed to provide warnings of Roundup’s risks. But jurors also ruled partially in Bayer’s favor by finding the product design wasn’t defective and the company wasn’t negligent.
Dennis was awarded $7 million in compensatory damages and $325 million in punitive damages.
In a statement to KNSD-TV, Bayer said it believes “we have strong arguments on appeal to get this unfounded verdict overturned and the unconstitutionally excessive damage award eliminated or reduced.”
“There were significant and reversible legal and evidentiary errors made during this trial,” Bayer added.
Bayer bought Monsanto for $63 billion in 2018 and has been trying to deal with thousands of claims and lawsuits related to Roundup. In 2020, Bayer announced it would pay up to $10.9 billion to settle some 125,000 filed and unfiled claims.
Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.
